BioMarin Pharmaceutical Inc. · Transaction Mar 6, 2023 · Filed Apr 17, 2023 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · BMRN
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
BioMarin Pharmaceutical Inc
Biotechnology
$58.44
Follow $BMRN
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $BMRN by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredThu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET · BMRN
MethodologyBMRN
BioMarin Pharmaceutical Inc
Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
63/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is BMRN moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About BioMarin Pharmaceutical Inc
PHARMACEUTICAL PREPARATIONSListed since
1999
Employees
3K
Country
US
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$58.44
Last session
Day high
$58.44
Last session
Day low
$58.44
Last session
Previous close
$58.44
52W high
$70.24
-16.80% from high
52W low
$49.67
43% of range
Market cap
$11.3B
P/E
156.78×
EPS
$1.84
Beta
-0.02
Shares out
193.6M
Avg volume
1.9M
VWAP
$58.44
Last session
Price history computed in-house
1W
-3.02%
1M
-12.74%
3M
-0.93%
1Y
+5.16%
YTD
-1.67%
SMA 50 $64.02 · below
SMA 200 $58.65 · below
52W position 43%
BMRN overview
Related filings and maps
Public disclosures
Congress activity in BMRN
Official filing ↗
Disclosed security · Transaction Oct 18, 2021 · Filed Nov 15, 2021 · $1,001 to $15,000
BMRN · Transaction Dec 30, 2020 · Filed Jan 11, 2021 · $15,001 to $50,000
Disclosed security · Transaction Sep 15, 2020 · Filed Oct 13, 2020 · $1,001 to $15,000
Disclosed security · Transaction Dec 16, 2019 · Filed Jan 6, 2020 · $1,001 to $15,000
Federal contracts
BMRN contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for BMRN in this window.
Lobbying spend
BMRN lobbying filings, year to date.
Registered lobbying filings matched to BioMarin Pharmaceutical Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for BMRN in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for BMRN.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.